Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
about
Neural KCNQ (Kv7) channelsNew molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channelsCharacterization of KCNQ5/Q3 potassium channels expressed in mammalian cellsMolecular targets for antiepileptic drug developmentIon channels as drug targets in central nervous system disordersNew and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapyHomeostasis or channelopathy? Acquired cell type-specific ion channel changes in temporal lobe epilepsy and their antiepileptic potentialThe acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytesRetigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 MutationsSelective interaction of syntaxin 1A with KCNQ2: possible implications for specific modulation of presynaptic activity.Unraveling monogenic channelopathies and their implications for complex polygenic diseaseMolecular expression and pharmacological evidence for a functional role of kv7 channel subtypes in Guinea pig urinary bladder smooth muscleAugmentation of M-type (KCNQ) potassium channels as a novel strategy to reduce stroke-induced brain injury.Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizuresKV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.Characteristics and molecular basis of celecoxib modulation on K(v)7 potassium channels.Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.Clinical utility of adjunctive retigabine in partial onset seizures in adults.The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.Atomic basis for therapeutic activation of neuronal potassium channels.Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine.One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.Retigabine holds KV7 channels open and stabilizes the resting potential.Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channelsDynamic subunit stoichiometry confers a progressive continuum of pharmacological sensitivity by KCNQ potassium channels.A review of potassium channels in bipolar disorder.Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.Nervous system KV7 disorders: breakdown of a subthreshold brake.Action potential initiation and propagation: upstream influences on neurotransmissionK+ channel modulators for the treatment of neurological disorders and autoimmune diseasesFunctional effects of KCNQ K(+) channels in airway smooth musclePotassium channels in peripheral pain pathways: expression, function and therapeutic potential.Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.M-currents (Kv7.2-7.3/KCNQ2-KCNQ3) Are Responsible for Dysfunctional Autonomic Control in Hypertensive Rats.Voltage-gated potassium channels as therapeutic targets.Heteromeric Kv7.2/7.3 channels differentially regulate action potential initiation and conduction in neocortical myelinated axons.Generation of Local CA1 γ Oscillations by Tetanic Stimulation.Potassium Channels in Epilepsy.
P2860
Q24644947-879F55D7-6C20-48B6-B8C3-2A5497B35120Q24654230-B2C9BE98-5EF7-4108-A44B-FF7EA320DD96Q24674102-1071EEE0-B1D1-4CB2-9517-D19ADA752439Q24683346-B7A2A0D0-633E-4E71-A5A0-81F6EF0D3DD1Q27004533-01DB7519-D39A-4837-BBF6-D8EF2757118AQ27007942-ACE95EA1-E06A-4307-8F13-4A504F45C665Q28080655-531DA5CB-8880-4EAB-B508-BFE85F9934A3Q28472214-A22EC738-C9BD-4697-A911-1B786897B4DBQ28550367-69AB4383-8029-4852-82AF-19899D6F6856Q33493069-3079C8D7-2FB0-4AC3-8A23-97002640287AQ33905030-08FFF54F-5E51-4D7E-8AB6-F9B18FFD527CQ35000941-D84361E9-E603-4D13-97F3-A91F90DB1EC5Q35044810-ED59F9FC-EE90-4D05-B521-B60AFD17D457Q35117817-2D5D7106-C82F-4ECB-BBC6-85F915996C1DQ35228397-BD3575B3-BA37-4657-95CA-93693658814AQ35593089-B4AAB4B7-40CC-4E17-B1F2-BCD7DE6BF027Q35683922-14335D7F-2FF6-4A74-B7C3-EEDC6B409280Q35717049-64F89EE8-164A-48CD-9350-5756BAFE0381Q35872543-236D2571-5AF6-4734-9F54-555ECEC72BBFQ36033788-0705F12A-E940-4B56-A097-3BB46611E228Q36144410-D1295D4D-CD25-4604-AE7C-EA6365A3BA70Q36548403-0FE05893-6517-42F6-ADA8-670C48B24074Q36603168-52E3725E-CF0A-4C35-B7A9-0CA214AB6B22Q36634324-4FC3C405-24EB-4D34-9152-0D23B2522F60Q36884049-8130E90B-98F6-4881-9A22-A642F673E3F8Q36884182-6ECE0799-D1E4-4328-88A4-30C3397462D3Q36917377-135D9700-8DEE-4128-AA44-C73135C49E1FQ36958975-EE383D0E-30BC-4275-8593-FDA4156A5079Q36980156-5A152EE4-CA1F-402D-AA20-5CE85A63E337Q37073177-0A49F324-060C-4D7F-9681-75467461E27AQ37160148-3BB5EB67-8AF8-4D54-8BA7-37949A5CE218Q37162392-B68E22E3-E263-4F4A-844B-27BCBEBFEE60Q37217408-512AF9B0-08D1-4038-817D-F4E9DCDDD38FQ37362041-A05FD676-F5B7-4F17-BB80-AC6CAD3BDEA2Q37415814-12FE1845-8227-450B-AF25-DD76DB20881AQ37447296-120014E1-020F-4C99-90A8-4E0C2CF06044Q37464784-E10B6118-3559-4940-9888-E46EE2FC0009Q37617404-6F4BB175-5956-4483-9DD0-9890E15A8665Q38412323-B0B7E041-7231-4171-920A-05AD4FA99664Q38824328-110DB76C-DDB0-4CFE-A3B9-5F70C0934D77
P2860
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@ast
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@en
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@nl
type
label
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@ast
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@en
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@nl
prefLabel
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@ast
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@en
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@nl
P2093
P1476
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
@en
P2093
P304
P407
P577
2000-09-01T00:00:00Z